A US Biosimilar Turning Point Approaches, With Work To Do
Executive Summary
2022 will be an important year for biosimilar manufacturers as the market expands into new areas like ophthalmology and insulin, and as the Humira US biosimilar entry nears in 2023.
You may also be interested in...
New Biosimilars Council Head Seeks Insulin Lessons As More Biosimilar Launches Loom
Craig Burton, who replaces the FDLI-bound Christine Simmon, tells the Pink Sheet that fighting rebating practices which harm insulin patients now can pave the way for successful launches of Humira biosimilars next year. Biosimilar markets should not be ‘winner-take-all,’ he says.
505(b)(2)-Like Pathway For Biologics May Gain Renewed Interest With Senate User Fee Bill Pending
Draft legislative text would allow some biologics and biosimilars to rely on published literature or other information and avoid some clinical studies, but the wide FDA discretion also included could raise more questions.
505(b)(2)-Like Pathway For Biologics May Gain Renewed Interest With Senate User Fee Bill Pending
Draft legislative text would allow some biologics and biosimilars to rely on published literature or other information and avoid some clinical studies, but the wide FDA discretion also included could raise more questions.